Announcements Trials
Browse Landscape

Status

Completed 81Recruiting 36Terminated 31Active not recruiting 24Withdrawn 7Unknown 5Not yet recruiting 3Suspended 2Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 6Gynecologic 4Genitourinary 3Gastrointestinal 3Thoracic 2Lymphoid 2Breast 2Plasma cell 1Myeloid 1Dermatologic 1CNS 1

Conditions

Melanoma 5Pancreatic Neoplasms 2Ovarian Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Merkel Cell 1

Interventions

balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Sarcoma × Dermatologic × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡